US15102K1007
© Globe Newswire
26.11.2025
CELC
LISTED
NASDAQ
Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium
News Preview
MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract was accepted for an oral presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS) and is now available on the SABCS website. The 2...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.11.2025
CELC
LISTED
NASDAQ
Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference
News Preview
MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the 8th Annual Evercore Healthcare Conference to be held in Miami, Florida on December 2-4, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.11.2025
CELC
LISTED
NASDAQ
Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
News Preview
MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion of the submission of its New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for gedatolisib in hormone receptor posit...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
05.11.2025
CELC
LISTED
NASDAQ
Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call
News Preview
MINNEAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2025 after the market closes on Wednesday, November 12, 2025. Management will host a webcast/t...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
04.11.2025
CELC
LISTED
NASDAQ
Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference
News Preview
MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Stifel 2025 Healthcare Conference to be held in New York on November 11-13, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
18.10.2025
CELC
LISTED
NASDAQ
Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer
News Preview
MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced detailed efficacy and safety results from the PIK3CA wild-type (“WT”) cohort of the Phase 3 VIKTORIA-1 clinical trial of gedatolisib, an investigational pan-PI...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.10.2025
CELC
LISTED
NASDAQ
Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)
News Preview
MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced updated clinical results from the Phase 1 portion of a clinical trial evaluating gedatolisib in combination with Nubeqa® (darolutamide), an androgen receptor i...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.10.2025
CELC
LISTED
NASDAQ
Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial
News Preview
MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced updates on the status of the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial evaluating gedatolisib plus fulvestrant with and without palbociclib...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
CELC
LISTED
NASDAQ
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
News Preview
USA News Group
News Commentary
Issued on behalf of GT Biopharma, Inc.
VANCOUVER, BC, Oct. 7, 2025 /CNW/ -- USA...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
CELC
LISTED
NASDAQ
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
News Preview
USA News Group
News Commentary
Issued on behalf of GT Biopharma, Inc.
VANCOUVER, BC, Oct. 7, 2025 /PRNewswire/...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
CELC
LISTED
NASDAQ
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
News Preview
USA News Group
News Commentary
Issued on behalf of GT Biopharma, Inc.
VANCOUVER, BC, Oct. 7, 2025 /PRNewswire/...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
CELC
LISTED
NASDAQ
Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress
News Preview
MINNEAPOLIS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that a late breaking abstract reporting clinical data from the Phase 3 VIKTORIA-1 trial has been selected for an oral presentation at the upcoming European So...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
27.08.2025
CELC
LISTED
NASDAQ
Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA’s Real-Time Oncology Review Program
News Preview
MINNEAPOLIS, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the U.S. Food and Drug Administration (“FDA”) agreed to accept its New Drug Application (“NDA”) for gedatolisib in HR+/HER2- advanced breast cancer (“ABC”) for...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.08.2025
CELC
LISTED
NASDAQ
Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call
News Preview
MINNEAPOLIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2025 after the market closes on Thursday, August 14, 2025. Management will host a webcast/tel...
Themefolio
Profiler
Peergroup
© PR Newswire
29.07.2025
CELC
LISTED
NASDAQ
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments
News Preview
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, B.C., July 29, 2025 /PRNewswire/ -- Equity Insider News Commentary – The average age of cancer patients is getting younger, as experts are urgently examining the rise of early-onset incidence across several different cancer types. According to the Cancer Discovery study from the National Canc...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.07.2025
CELC
LISTED
NASDAQ
Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer
News Preview
MINNEAPOLIS, July 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the Company will hold a conference call and webcast on Monday, July 28, 2025 at 8:00 AM ET to disclose the topline results of the PIK3CA Wild-Type Cohort from...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.07.2025
CELC
LISTED
NASDAQ
Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042
News Preview
MINNEAPOLIS, July 14, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the issuance of U.S. Patent No. 12,350,276 covering the clinical dosing regimen for its lead drug candidate, gedatolisib, in ER+/HER2- breast cancer patients....
Themefolio
Profiler
Peergroup
© PR Newswire
08.07.2025
CELC
LISTED
NASDAQ
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention
News Preview
Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. gove...
Themefolio
Profiler
Peergroup
© PR Newswire
08.07.2025
CELC
LISTED
NASDAQ
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention
News Preview
Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. gove...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
CELC
LISTED
NASDAQ
Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib
News Preview
• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”),the six-month radiographic progression free survival (“rPFS”) rate was 66%...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.05.2025
CELC
LISTED
NASDAQ
Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences
News Preview
MINNEAPOLIS, May 21, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following invest...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.05.2025
CELC
LISTED
NASDAQ
Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call
News Preview
MINNEAPOLIS, May 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2025 after the market closes on Wednesday, May 14, 2025. Management will host a webcast/telecon...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.04.2025
CELC
LISTED
NASDAQ
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
News Preview
MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following inve...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.03.2025
CELC
LISTED
NASDAQ
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call
News Preview
MINNEAPOLIS, March 24, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2024 after the market closes on Monday, March 31, 2025. Management will host a...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.02.2025
CELC
LISTED
NASDAQ
Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences
News Preview
MINNEAPOLIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following inves...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2024
CELC
LISTED
NASDAQ
Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium
News Preview
Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2024
CELC
LISTED
NASDAQ
Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences
News Preview
MINNEAPOLIS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following inves...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2024
CELC
LISTED
NASDAQ
Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call
News Preview
MINNEAPOLIS, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2024 after the market closes on Thursday, November 14, 2024. Management will host a webcast/te...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.08.2024
CELC
LISTED
NASDAQ
Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call
News Preview
MINNEAPOLIS, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2024 after the market closes on Wednesday, August 14, 2024. Management will host a webcast/te...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.05.2024
CELC
LISTED
NASDAQ
Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing
News Preview
MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it plans to initiate a Phase 3 clinical trial to evaluate gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.05.2024
CELC
LISTED
NASDAQ
Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call
News Preview
MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2024 after the market closes on Wednesday, May 15, 2024. Management will host a webcast/telecon...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
